

Announcement No. 23/2007

To OMX Nordic Exchange Copenhagen and the press.

Copenhagen, 18 December 2007

**Exiqon A/S increases its share capital in connection with exercise of warrants**

Exiqon A/S has today 18 December 2007 completed an increase of its share capital by DKK 34,262, nominal value, as a result of employees exercising warrants. The increase of the share capital is expected to be registered with the Danish Commerce and Companies Agency today 18 December 2007. The registered share capital subsequently amounts to DKK 24,441,064, nominal value, divided into 24,441,064 shares of DKK 1.00, nominal value, each.

The new shares are in accordance with the terms of the warrants exercised subscribed for without any preemption rights for the existing shareholders of the company, and the subscription price was DKK 9.50 per share of DKK 1.00, nominal value, each.

The new shares shall carry a right to any dividend for the financial year 2007 from the time of registration of the capital increase.

Following the exercise the number of outstanding warrants is 2,205,232.

**For additional information please contact**

CEO Lars Kongsbak, tel. +45 4565 0450 or +45 4090 2101

CFO, Hans Henrik Chrois Christensen tel.+45 4565 0953 or +45 4090 2131

**About Exiqon**

Exiqon is a leading provider of high-value gene expression analysis products for the life sciences, research and drug discovery industries. Exiqon's rapidly growing product offerings integrate innovative chemistries with web-based software tools to help scientists achieve rapid and reliable results. Exiqon markets its products directly on [www.exiqon.com](http://www.exiqon.com) or through distributors in Asia and parts of EU, as well as through its dedicated sales force in the US and Europe. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark and in Boston, USA. Please visit our web-site at [www.exiqon.com](http://www.exiqon.com).

**DISCLAIMER**

**Forward-looking statements**

This announcement contains forward-looking statements regarding the Company's future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of the Company's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. The Company's operations are characterised by the fact that its actual results may deviate significantly from those described herein as anticipated, believed, estimated or expected.